Global Summary of New Drug Compound Patents and Expiration Time

1. Zepatier Mercadon Hepatitis C Cocktail, the active ingredients are Elbasvir and Grazoprevir. FDA approval date: January 28, 2016. The compound patents of the two components in China are CN103880862 (real trial) and CN102159285 (right) respectively, and the patent coverage periods are 2030 and 2019 respectively.

2. A new antiepileptic drug Briviact UCB, the active ingredient of which is buvalacetam (Brivaracetam), has been approved by FDA on February 18, 2016. The patent CN1208319 of the compound has been authorized and the patent coverage period is 2021.

3. Venclexta AbbVie's anti-leukemia drug is mainly composed of Venetoclax. FDA approval date is April 11, 2016. The compound patent CN102448959 has been authorized and the patent coverage period is 2030.

4. Nuplazid Acadia's blockbuster anti-PD drug, the main one is pimovanserin (Pimavanserin). FDA approval date is April 29, 2016. The compound patent CN1816524 has been authorized and the patent coverage period is 2024.

5. Ocaliva Intercept Pharmaceutical's blockbuster PBC drug, the main component is obeticholic acid (Obeticholic Acid). FDA approval date is May 27, 2016. The compound patent has not entered China, but there is a crystal form patent.

6. Axumin BLUE EARTH contrast agent is used for prostate cancer examination. The main component is Fluciclovine F-18. FDA approval date is May 27, 2016. No Chinese congeners have been found in the compound patent WO9717092.

7. Epclusa Gilid's second-generation hepatitis C cocktail is mainly composed of Sofosbuvir and Velpatasvir. FDA approval date is June 28, 2016. Sophibuvir's patent in China has been authorized, with the patent coverage period until 2024. The Velpatasvir compound patent CN104292256 is still under trial, with the patent coverage period until 2030.

8. Xiidra Shire's blockbuster new drug for dry eye disease, the main component is Lifitegrast, the FDA approval date is July 11, 2017, the compound patent CN102617557 is still under trial, and the patent coverage period is 2026.

9. Eucrisa Pfizer's eczema blockbuster drug, the main ingredient is Crisaborole, and the FDA approval date is December 14, 2016. The compound patent CN101160124 has no right in China.

10. Rubraca Clovis's blockbuster new ovarian cancer drug, the main component is Rucaparib, the FDA approval date is December 19, 2016, the compound patent CN100418967 has been authorized, and the patent coverage period is 2020.

11. Savaysa the first three total anticoagulant, the main component is edasaban (Edoxaban),FDA approval date is January 8, 2015, the compound patent CN1826333 has been authorized, the patent coverage period until 2022.

12. Ibrance Pfizer's blockbuster new breast cancer drug, the main component is Palbociclib, the FDA approval date is February 3, 2015, the compound patent CN101001857 has been authorized, and the patent coverage period is 2023.

13. The new thyroid cancer drug Lenvima Eisai is mainly lenvatinib (Lenvatinib). FDA approval date is February 13, 2015. The compound patent CN1308310 has been authorized and the patent coverage period is 2021.

14. Farydak Novartis's new multiple myeloma drug, the main component is Pabinostat (Panobinostat),FDA approval date is February 23, 2015, compound patent CN1300110 has been authorized, patent coverage period until 2021.

15. Cresemba antifungal drug of Astelia, the main component is isaconazole (Isavuconazonium). FDA approval date is March 6, 2015. The compound patent CN1185230 has been authorized and the patent coverage period is 2020.

16. Viberzi Furiex's new drug for irritable bowel syndrome, the main component is Aishadulin (Eluxadoline). FDA approval date is May 27, 2015. The compound patent CN1950342 has been authorized and the patent coverage period is 2025.

17. The injectable anti-platelet aggregation drug of Kengreal Medicines Company has been approved by FDA on April 15, 2015. The main component is Changrello (Cangrelor), and the patent CN1042430 of the compound has expired.

18. Rexulti the antipsychotic drug of Otsuka Pharmaceutical, the main component is Brexpiprazole, the FDA approval date is July 10, 2015, the compound patent CN101155804 has been authorized, and the patent coverage period is 2026.

19. Odomzo Novartis's new anticancer drug, the main component is Sonidegib, and the FDA approval date is July 24, 2015. The compound patent CN102746285 enters the review process. If authorized, the right protection period will end in 2027.

20. The main component of the new hepatitis C drug Daklinza BMS is dacalavir (Daclatasvir). FDA approval date is July 24, 2015. The compound patent CN101558059 has been authorized and the patent coverage period is 2027.

21. Addyi Boehringer Ingham's female Viagra is mainly composed of flupanserin (Flibanserin). FDA approval date is August 18, 2015. No Chinese compound family patent for this product has been found, and the US compound patent has expired.

22. The antiemetic drug of Varubi Tesaro Company is mainly composed of rolapitant (Rolapitant). FDA approval date is September 2, 2015. The compound patent CN1606545 has been authorized and the patent coverage period is 2022.

23. The antipsychotic drug of Vraylar Forest Company is mainly carbimazine (Cariprazine). FDA approval date is September 17, 2015. The compound patent CN1829703 has been authorized and the patent coverage period is 2024.

24. Lonsurf the compound anticancer drug of Dazheng Pharmaceutical, the main components are Trifluridine and Tipiracil, and the FDA approval date is September 22, 2015. The CN1144587 combination drug patent has been authorized and the patent coverage period is until 2020.

25. The HIV cocktail Genvoya Jilid is mainly composed of Elvitegravir, Cobicistat, Emtricitabine and tenofovir disoproxil. FDA approval date is November 5, 2015. The patent for combination has been authorized and the patent coverage period will be 2031.

26. Cotellic Genentech's anticancer drug, the main component is Cobimetinib,FDA approval date is November 10, 2015, compound patent CN101365676 has been authorized, and the patent protection period will be 2026

27. Tagrisso AstraZeneca's new lung cancer drug, the main component is Osimertinib, the FDA approval date is November 13, 2015, the compound patent CN103702990 has been authorized, and the patent coverage period is 2032.

28. The main component of the new multiple myeloma drug Millennium by Ninlaro is Ixazomib. The FDA approval date is November 20, 2015. The compound patent CN103435638 is still under trial. If authorized, the patent protection period will be 2029.

29. Alecensa Roche's new lung cancer drug, the main component is Alectinib, the FDA approval date is December 11, 2015, the compound patent CN102459172 has been authorized, and the patent protection period will be 2030.

30. Bridion Organon Company's new muscle relaxation antagonist, the main component is Sugammadex,FDA approval date is December 15, 2015, the compound patent CN1188428 has been authorized, the patent coverage period until 2020.

31. Uptravi Actelion Company's blockbuster new drug for pulmonary hypertension, the main component is Selexipag,FDA approval date is December 22, 2015, compound patent CN1301973 has been authorized, patent coverage period until 2022.

32. Zurampic AstraZeneca's new anti-gout drug, the main component is Lesinurad, the FDA approval date is December 22, 2015, the compound patent CN101083987 has been authorized, and the patent coverage period is 2025.

33. Yondelis Janssen Prods anticoagulant, the main component is Trabectedin,FDA approval date is October 21, 2015, no Chinese compound patent, the U.S. patent coverage period until 2024.

34. Veltassa Relypsa Company's hypokalemic drugs, the main component is Patiromer,FDA approval date is October 21, 2015, China has not seen compound patents, and the patent US07556799 for indications expires in 2024.

35. Entresto Novartis's blockbuster anti-heart failure drug, the main components are valsartan and sacubitril, and the FDA approval date is July 7, 2015. The patent for valsartan compound has expired, and the sacubitril compound patent CN102091330 has been authorized, but it is in the reexamination process and may be subject to patent challenges. The normal expiration event for the patent is 2023 and the combination drug patent is 2027.

36. Orkambi vertex's blockbuster new anti-cystic fibrosis drug, the main components are Lumacaftor and Ivacaftor, the FDA approval date is July 2, 2015, the compound patents are CN101384172 and CN103641765 respectively, and the patent coverage period is 2025 and 2026 respectively.

37. Xadago Zambon's new antiepileptic drug, the main component of which is safinamide, has been approved by EMA on February 24, 2015. The compound patent CN101687773 has been authorized and the patent coverage period is until 2026.

38. Zafatek Takeda's long-acting oral hypoglycemic drug, the main component is troxagliptin, PMDA approval date is March 26, 2015, the compound patent CN1926128 was rejected, and Takeda has applied for several divisions, which are still under trial.

39. Zebiax Maruho new antibacterial drug, the main component is Ozenoxacin,PMDA approval date is July 3, 2015, compound patent CN1152029 has been authorized, patent protection period until 2019.

40. Marizev Mercadon long-acting oral hypoglycemic drug, the main component is Omarigliptin,PMDA approval date is September 28, 2015, compound patent CN102272136 has been authorized, patent protection period until 2029.

41. Ongentys Bial's new anti-Parkinson drug, the main component is Opicapone,EMA approval date is April 24, 2016, the compound patent CN101248064 has been authorized, and the patent protection period will be 2026.

42. Wakix Bioprojet Company's new drug for sleep disorders, the main component is Pitolisant, the compound patent WO00006254 expires in 2019, China has not seen the same family.

43. The new lung cancer drug of Olita Hanmei Company was approved by KFDA in May 2016. The main component is Olmutinib. The compound patent CN102947316 has been authorized and the patent protection period is until 2031.